

We claim:

1. A peptide having an amino acid sequence selected from the group consisting of:

- Sub a6*
- (a) HHARL;
 - (b) HARL;
 - (c) HARLI;
 - (d) HARLIL;
 - (e) HHARLCL;
 - (f) ARLIL;
 - (g) HHARLIF;
 - (h) THARDIL;
 - (i) ARLI;
 - (j) ARL;
 - (k) HARLCL;
 - (l) ARLCL;
 - (m) ARCL;
 - (n) MFARLIL;
 - (o) FARLIL;
 - (p) FARLI;
 - (q) FARL;
 - (r) HARLIF;
 - (s) ARLIF; and homologs thereof.

2. A composition comprising one or more peptides according to claim 1 and a carrier therefor.

3. A peptide having an amino acid sequence selected from the group consisting of:

- Sub a7*
- (a) LHARLCLANFCGRNRV;
 - (b) LARLCLANFCGNNNV;
 - (c) CARYRTGHHARLM;

- Sub 7
a
- (d) ~~HHARLPLANFCG;~~
 - (e) ~~RTGHHARLC*LANFC;~~
 - (f) ~~CESARYRTGHHARLC*;~~
 - (g) ~~DNTHHARLIL;~~
 - (h) ~~SHHARLIL; and homologs thereof.~~

4. A composition comprising one or more peptides according to claim 3 and a carrier therefor.

10 Sub 8
a 5. A peptide having the amino acid sequence A R L I, and comprising at least one and up to 25 additional amino acids flanking either the 3' or 5' end of the peptide.

6. A peptide having the amino acid sequence H A R L, and comprising at least one and up to 25 additional amino acids flanking either the 3' or 5' end of the peptide.

7. A peptide having the amino acid sequence F A R L, and comprising at least one and up to 25 additional amino acids flanking either the 3' or 5' end of the peptide.

8. A peptide having the amino acid sequence A R L, and comprising at least one and up to 25 additional amino acids flanking either the 3' or 5' end of the peptide.

Sub 9
25 9. A peptide having the amino acid sequence A R L C, and comprising at least one and up to 25 additional amino acids flanking either the 3' or 5' end of the peptide.

10. A polymer of a "Harlil" peptide sequence comprising at least two repetitions of the peptide.

SEQ ID NO: 2 residues 46-51

30 Sub 10
a 11. A nucleic acid encoding an amino acid sequence selected from the group consisting of:

- (a) ~~HHARL;~~

- 5 (b) HARL;
(c) HARLI;
(d) HARLIL;
(e) HHARLCL;
(f) ARLIL;
(g) HHARLIF;
(h) THARLIL;
(i) ARLI;
(j) ARL;
10 (k) HARLCL;
(l) ARLCL;
(m) ARCL;
(n) MFARLIL;
(o) FARLIL;
(p) FARLI;
(q) FARL;
(r) HARLIF;
15 (s) ARLIF; and homologs of such amino acid sequences.

20 12. A composition comprising one or more nucleic acids according to claim 11 and a pharmaceutically acceptable carrier therefor.

13. A nucleic acid encoding an amino acid sequence selected from the group consisting of::

- 25 (a) LHARLCLANFCGRNRV;
(b) LARLCLANFCGNNNV;
(c) CARYRTGHHARLM;
(d) HHARLPANFCG;
(e) RTGHHARLC*LANFC;
30 (f) CESARYRTGHHARLC*;
(g) DNTHHARLIL;

Sub
all

(h) ~~S H H A R L I L~~; and homologs thereof.

14. A composition comprising one or more nucleic acids according to claim 13 and a carrier therefor.

5

15. A nucleic acid encoding the amino acid sequence A R L I, and comprising residues encoding at least one and up to 25 additional amino acids flanking either the 3' or 5' end of the peptide.

10

16. A nucleic acid encoding the amino acid sequence H A R L and comprising residues encoding at least one and up to 25 additional amino acids flanking either the 3' or 5' end of the peptide.

15

17. A nucleic acid encoding the amino acid sequence F A R L and comprising residues encoding at least one and up to 25 additional amino acids flanking either the 3' or 5' end of the peptide.

20

18. A nucleic acid encoding the amino acid sequence A R L and comprising residues encoding at least one and up to 25 additional amino acids flanking either the 3' or 5' end of the peptide.

19. A nucleic acid encoding the amino acid sequence A R L C, and comprising residues encoding at least one and up to 25 additional amino acids flanking either the 3' or 5' end of the peptide.

25

Sub
all

20. An antibody which specifically recognizes a peptide sequence having an amino acid sequence selected from the group consisting of:

30

- (a) H H A R L;
- (b) H A R L;
- (c) H A R L I;
- (d) H A R L I L;
- (e) H H A R L C L;
- (f) A R L I L;
- (g) H H A R L I F;

- 5
- (h) THARLIL;
 - (i) ARLI;
 - (j) ARL;
 - (k) HARLCL;
 - (l) ARLCL;
 - (m) ARCL;
 - (n) MFARLIL;
 - (o) FARLIL;
 - (p) FARLI;
 - (q) FARL;
 - (r) HARLIF;
 - (s) ARLIF; and homologs thereof.

10
15 21. An antibody which specifically recognizes a peptide sequence having an amino acid sequence selected from the group consisting of:

- (a) LHARLCLANFCGRNRV;
- (b) LARLCLANFCGNNNV;
- (c) CARYRTGHHARLM;
- (d) HHARLPLANFCG;
- (e) RTGHHARLC*LANFC;
- (f) CESARYRTGHHARLC*;
- (g) DNTHHARLIL;
- (h) SHHARLIL; and homologs thereof.

25 22. An antibody which specifically recognizes a peptide sequence having an amino acid sequence selected from the group consisting of:

- 30
- (a) ARLI;
 - (b) HARL;
 - (c) FARL;
 - (d) ARL; and
 - (e) ARLC,

wherein the peptide comprises at least one and up to 25 additional amino acids flanking either the 3' or 5' end of the peptide.

23. A mimetic of a peptide having an amino acid sequence selected from the group consisting of:

- (a) HHARL;
- (b) HARL;
- (c) HARLI;
- (d) HARLIL;
- (e) HHARLCL;
- (f) ARLIL;
- (g) HHARLIF;
- (h) THARLIL;
- (i) ARLI;
- (j) ARL;
- (k) HARLCL;
- (l) ARLCL;
- (m) ARCL;
- (n) MFARLIL;
- (o) FARLIL;
- (p) FARLI;
- (q) FARL;
- (r) HARLIF;
- (s) ARLIF; and homologs of such amino acid sequences.

24. A mimetic of a peptide having an amino acid sequence selected from the group consisting of:

- (a) LHARLCLANFCGRNRV;
- (b) LARLCLANFCGNNNV;
- (c) CARYRTGHHARLM;
- (d) HHARLPLANFCG;

See
a12
cont

- (e) RTGHHARLC*LANFC;
- (f) CESARYRTGHHARLC*;
- (g) DNTHHARLIL;
- (h) SHHARLIL; and homologs thereof.

5

25. A mimetic of a peptide having an amino acid sequence selected from the group consisting of:

- (a) ARLI;
- (b) HARL;
- (c) FARL;
- (d) ARL, and
- (e) ARLC;

10

wherein the NTP peptide comprises at least one and up to 25 additional amino acids flanking either the 3' or 5' end of the peptide.

15

26. A method for purifying NTP from a biological sample comprising:
- (1) contacting a biological sample with one or more peptides having an amino acid sequence selected from the group consisting of:

- (a) HHARL;
- (b) HARL;
- (c) HARLI;
- (d) HARLIL;
- (e) HHARLCL;
- (f) ARLIL;
- (g) HHARLIF;
- (h) THARLIL;
- (i) ARLI;
- (j) ARL;
- (k) HARLCL;
- (l) ARLCL;
- (m) ARCL;
- (n) MFARLIL;

20

30

Sub
A12
WBB

- (o) F A R L I L;
- (p) F A R L I;
- (q) F A R L;
- (r) H A R L I F;
- (s) A R L I F; and homologs of such amino acid sequences;

5

- (2) isolating the resulting Harlil peptide/NTP conjugates; and
- (3) separating NTP from the one or more Harlil peptides to obtain purified NTP.

10

- 27. A method for purifying NTP from a biological sample comprising:
- (1) contacting a biological sample with one or more peptides having an amino acid sequence selected from the group consisting of:

- (a) L H A R L C L A N F C G R N R V;
- (b) L A R L C L A N F C G N N N V;
- (c) C A R Y R T G H H A R L M;
- (d) H H A R L P L A N F C G;
- (e) R T G H H A R L C * L A N F C;
- (f) C E S A R Y R T G H H A R L C *;
- (g) D N T H H A R L I L;
- (h) S H H A R L I L; and homologs thereof;

20

- (2) isolating the resulting Harlil peptide/NTP conjugates; and
- (3) separating NTP from the one or more Harlil peptides to obtain purified NTP.

- 28. A method for purifying NTP from a biological sample comprising:
- (a) contacting a biological sample with one or more peptides having an amino acid sequence selected from the group consisting of:

- (i) A R L I;
- (ii) H A R L;
- (iii) F A R L;
- (iv) A R L; and
- (v) A R L C;

30

See
a12
corst

wherein the peptide comprises at least one and up to 25 additional amino acids flanking either the 3' or 5' end of the peptide;

- (b) isolating the resulting Harlil peptide/NTP conjugates; and
- (c) separating NTP from the one or more Harlil peptides to obtain purified NTP.

29. A diagnostic test for determining the presence of Alzheimer's Disease or other neurodegenerative disorder comprising:

- (1) contacting a biological sample with one or more peptides having an amino acid sequence selected from the group consisting of:

- (a) H H A R L I;
- (b) H A R L I;
- (c) H A R L I;
- (d) H A R L I L;
- (e) H H A R L C L;
- (f) A R L I L;
- (g) H H A R L I F;
- (h) T H A R L I L;
- (i) A R L I;
- (j) A R L;
- (k) H A R L C L;
- (l) A R L C L;
- (m) A R C L;
- (n) M F A R L I L;
- (o) F A R L I L;
- (p) F A R L I;
- (q) F A R L;
- (r) H A R L I F;
- (s) A R L I F; and homologs of such amino acid sequences;

- (2) determining the amount of NTP present in the sample; and

*Sub
a12
cont*

- (3) determining whether the amount of NTP present in the sample is above a threshold amount indicative of the presence of Alzheimer's Disease or other neurodegenerative disorder.

5 30. A diagnostic test for determining the presence of Alzheimer's Disease or other neurodegenerative disorder comprising:

- (1) contacting a biological sample with one or more peptides having an amino acid sequence selected from the group consisting of:
- (a) L H A R L C L A N F C G R N R V;
 - (b) L A R L C L A N F C G N N N V;
 - (c) C A R Y R T G H H A R L M;
 - (d) H H A R L P L A N F C G;
 - (e) R T G H H A R L C * L A N F C;
 - (f) C E S A R Y R T G H H A R L C *;
 - (g) D N T H H A R L I L;
 - (h) S H H A R L I L; and homologs thereof;
- (2) determining the amount of NTP present in the sample; and
- (3) determining whether the amount of NTP present in the sample is above a threshold amount indicative of the presence of Alzheimer's Disease or other neurodegenerative disorder.

31. A diagnostic test for determining the presence of Alzheimer's Disease or other neurodegenerative disorder comprising:

- (a) contacting a biological sample with one or more peptides having an amino acid sequence selected from the group consisting of:
- (i) A R L I;
 - (ii) H A R L;
 - (iii) F A R L;
 - (iv) A R L; and
 - (v) A R L C;

wherein the peptide comprises at least one and up to 25 additional amino acids flanking either the 3' or 5' end of the peptide;

- (b) determining the amount of NTP present in the sample; and

- (c) determining whether the amount of NTP present in the sample is above a threshold amount indicative of the presence of Alzheimer's Disease or other neurodegenerative disorder.

5 32. A diagnostic kit for determining the presence of Alzheimer's Disease or other neurodegenerative disorder comprising:

- (1) one or more peptides having an amino acid sequence selected from the group consisting of:

- 10 (a) H H A R L;
(b) H A R L;
(c) H A R L I;
(d) H A R L I L;
(e) H H A R L C L;
(f) A R L I L;
(g) H H A R L I F;
(h) T H A R L I L;
(i) A R L I;
(j) A R L;
(k) H A R L C L;
20 (l) A R L C L;
(m) A R C L;
(n) M F A R L I L;
(o) F A R L I L;
(p) F A R L I;
(q) F A R L;
(r) H A R L I F;
(s) A R L I F; and homologs of such amino acid sequences; and

- (2) suitable reagents.

30 33. A diagnostic kit for determining the presence of Alzheimer's Disease or other neurodegenerative disorder comprising:

(1) one or more peptides having an amino acid sequence selected from the group consisting of:

- (a) L H A R L C L A N F C G R N R V;
- (b) L A R L C L A N F C G N N N V;
- (c) C A R Y R T G H H A R L M;
- (d) H H A R L P L A N F C G;
- (e) R T G H H A R L C * L A N F C;
- (f) C E S A R Y R T G H H A R L C *;
- (g) D N T H H A R L I L;
- (h) S H H A R L I L; and homologs thereof; and

(2) suitable reagents.

34. A diagnostic kit for determining the presence of Alzheimer's Disease or other neurodegenerative disorder comprising:

(a) one or more peptides having an amino acid sequence selected from the group consisting of:

- (i) A R L I;
- (ii) H A R L;
- (iii) F A R L;
- (iv) H A R L I;
- (v) A R L C;

wherein the peptide comprises at least one and up to 25 additional amino acids flanking either the 3' or 5' end of the peptide; and

(b) suitable reagents.

35. A method of using a peptide as an analogue for NTP in a therapeutic or diagnostic assay, comprising replacing NTP with the peptide in such an assay, wherein the peptide has an amino acid sequence selected from the group consisting of:

- (a) H H A R L;
- (b) H A R L;
- (c) H A R L I;
- (d) H A R L I L;

*Sub
9/2
25
cont*

- (e) HHARLCL;
- (f) ARLIL;
- (g) HHARLIF;
- (h) THARLIL;
- (i) ARLI;
- (j) ARL;
- (k) HARLCL;
- (l) ARLCL;
- (m) ARCL;
- (n) MFARLIL;
- (o) FARLIL;
- (p) FARLI;
- (q) FARL;
- (r) HARLIF;
- (s) ARLIF; and homologs of such amino acid sequences.

36. A method of using a peptide as an analogue for NTP in a therapeutic or diagnostic assay, comprising replacing NTP with the peptide in such an assay, wherein the peptide has an amino acid sequence selected from the group consisting of:

- (a) LHARLCLANFCGRNRV;
- (b) LARLCLANFCGNNNV;
- (c) CARYRTGHHARLM;
- (d) HHARLPLANFCG;
- (e) RTGHHARLC*LANFC;
- (f) CESARYRTGHHARLC*;
- (g) DNTHHARLIL;
- (h) SHHARLIL; and homologs thereof.

37. A method of using a peptide as an analogue for NTP in a therapeutic or diagnostic assay, comprising replacing NTP with the peptide in such an assay, wherein the peptide has an amino acid sequence selected from the group consisting of:

- (a) A R L I;
- (b) H A R L;
- (c) F A R L;
- (d) A R L, and
- (e) A R L C;

wherein the peptide comprises at least one and up to 25 additional amino acids flanking either the 3' or 5' end of the peptide.

38. A method of using a peptide as a trap material in a diagnostic or therapeutic assay, wherein the peptide has an amino acid sequence selected from the group consisting of:

- (a) H H A R L;
- (b) H A R L;
- (c) H A R L I;
- (d) H A R L I L;
- (e) H H A R L C L;
- (f) A R L I L;
- (g) H H A R L I F;
- (h) T H A R L I L;
- (i) A R L I;
- (j) A R L;
- (k) H A R L C L;
- (l) A R L C L;
- (m) A R C L;
- (n) M F A R L I L;
- (o) F A R L I L;
- (p) F A R L I;
- (q) F A R L;
- (r) H A R L I F;
- (s) A R L I F; and homologs of such amino acid sequences.

39. A method of using a peptide as a trap material in a diagnostic or therapeutic assay, wherein the peptide has an amino acid sequence selected from the group consisting of:

- (a) L H A R L C L A N F C G R N R V;
- (b) L A R L C L A N F C G N N N V;
- (c) C A R Y R T G H H A R L M;
- (d) H H A R L P L A N F C G;
- (e) R T G H H A R L C * L A N F C;
- (f) C E S A R Y R T G H H A R L C *;
- (g) D N T H H A R L I L;
- (h) S H H A R L I L; and homologs thereof.

40. A method of using a peptide as a trap material in a diagnostic or therapeutic assay, wherein the peptide has an amino acid sequence selected from the group consisting of:

- (a) A R L I;
- (b) H A R L;
- (c) F A R L;
- (d) A R L, and
- (e) A R L C;

wherein the peptide comprises at least one and up to 25 additional amino acids flanking either the 3' or 5' end of the peptide.

41. A method of isolating immunoglobulins from a sample using a peptide comprising:

- (1) contacting a sample comprising immunoglobulins with at least two peptides to allow for immunoglobulin/ peptide interaction; and
- (2) isolating the resulting peptide/immunoglobulin conjugates, wherein the peptide has an amino acid sequence selected from

the group consisting of:

- (a) H H A R L;
- (b) H A R L;
- (c) H A R L I;

- (d) H A R L I L;
(e) H H A R L C L;
(f) A R L I L;
(g) H H A R L I F;
(h) T H A R L I L;
(i) A R L I;
(j) A R L;
(k) H A R L C L;
(l) A R L C L;
(m) A R C L;
(n) M F A R L I L;
(o) F A R L I L;
(p) F A R L I;
(q) F A R L;
(r) H A R L I F;
(s) A R L I F; and homologs of such amino acid sequences.

42. The method of claim 41, wherein the NTP peptide/immunoglobulin conjugates are isolated by precipitation.

43. The method of claim 41, wherein the NTP peptide/immunoglobulin conjugates are isolated on an affinity column.

44. The method of to claim 41, wherein the immunoglobulins are subsequently purified.

45. A method of isolating immunoglobulins from a sample using a peptide comprising:

- (1) contacting a sample comprising immunoglobulins with at least two peptides to allow for immunoglobulin/peptide interaction; and
- (2) isolating the resulting peptide/immunoglobulin conjugates, wherein the peptide has an amino acid sequence selected from the group consisting of:

- (a) L H A R L C L A N F C G R N R V;
 (b) L A R L C L A N F C G N N N V;
 (c) C A R Y R T G H H A R L M;
 (d) H H A R L P L A N F C G;
 (e) R T G H H A R L C * L A N F C;
 (f) C E S A R Y R T G H H A R L C *;
 (g) D N T H H A R L I L;
 (h) S H H A R L I L; and homologs thereof.

See
A13

10

46. The method of claim 45, wherein the peptide/immunoglobulin conjugates are isolated by precipitation.

15

47. The method of claim 45, wherein the peptide/immunoglobulin conjugates are isolated on an affinity column.

20

48. The method of to claim 45, wherein the immunoglobulins are subsequently purified.

See
A14

25

49. A method of isolating immunoglobulins from a sample using a peptide comprising:

- (a) contacting a sample comprising immunoglobulins with at least two peptides to allow for immunoglobulin/ peptide interaction; and
 (b) isolating the resulting peptide/immunoglobulin conjugates, wherein the peptide has an amino acid sequence selected from the group consisting of:
 (a) A R L I;
 (b) H A R L;
 (c) F A R L;
 (d) A R L ; and
 (e) A R L C;

30

wherein the peptide comprises at least one and up to 25 additional amino acids flanking either the 3' or 5' end of the peptide.

50. The method of claim 49, wherein the peptide/immunoglobulin conjugates are isolated by precipitation.

51. The method of claim 49, wherein the peptide/immunoglobulin conjugates
5 are isolated on an affinity column.

52. The method according to claim 49, wherein the immunoglobulins are subsequently purified.

10 53. A method for preventing NTP interacting through the Harlil domains comprising blocking one or more Harlil domains by use of one or more Harlil peptides, Harlil peptide mimetics, antibodies to such a domain, or a combination thereof.

15
20
25
30
35
40
45
50
55
60
65
70
75
80
85
90
95
100
105
110
115
120
125
130
135
140
145
150
155
160
165
170
175
180
185
190
195
200
205
210
215
220
225
230
235
240
245
250
255
260
265
270
275
280
285
290
295
300
305
310
315
320
325
330
335
340
345
350
355
360
365
370
375
380
385
390
395
400
405
410
415
420
425
430
435
440
445
450
455
460
465
470
475
480
485
490
495
500
505
510
515
520
525
530
535
540
545
550
555
560
565
570
575
580
585
590
595
600
605
610
615
620
625
630
635
640
645
650
655
660
665
670
675
680
685
690
695
700
705
710
715
720
725
730
735
740
745
750
755
760
765
770
775
780
785
790
795
800
805
810
815
820
825
830
835
840
845
850
855
860
865
870
875
880
885
890
895
900
905
910
915
920
925
930
935
940
945
950
955
960
965
970
975
980
985
990
995